EMEA-001220-PIP03-16

Key facts

Invented name
Olumiant
Active substance
baricitinib
Therapeutic area
Dermatology
Decision number
P/0291/2018
PIP number
EMEA-001220-PIP03-16
Pharmaceutical form(s)
Oral suspension
Condition(s) / indication(s)
Treatment of atopic dermatitis
Route(s) of administration
Oral use
Contact for public enquiries
Eli Lilly and Company Limited

Tel. +44 1276483000
E-mail: eu_paediatric@lilly.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating